Aldeyra Therapeutics (ALDX) Income from Non-Controlling Interests (2013)
Aldeyra Therapeutics (ALDX) posted Income from Non-Controlling Interests of $327.0 for Q4 2013.
Aldeyra Therapeutics (ALDX) Income from Non-Controlling Interests (2013) Analysis & Trends
Aldeyra Therapeutics' Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at $327.0 for Q4 2013.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $327.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $327.0 (changed N/A YoY) and the FY2013 annual result came in at $327.0, changed N/A from the prior year.
- Income from Non-Controlling Interests was $327.0 for Q4 2013 at Aldeyra Therapeutics.
- Across five years, Income from Non-Controlling Interests topped out at $327.0 in Q4 2013 and bottomed at $327.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 468.98 Bn | 464.19 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.24 Bn | 115.99 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.45 Bn | 61.70 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.04 Bn | 63.04 Bn | - | - |
| 8 | Argenx Se | 55.79 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | - |
| 10 | Aldeyra Therapeutics | 94.40 Mn | 94.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 327.00 |